RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2005; 94(06): 1338-1339
DOI: 10.1055/s-0037-1615589
DOI: 10.1055/s-0037-1615589
Letters to the Editor
Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: In vitro and in vivo evidence
Authors
Grant support: This work was supported by a grant from the Bundesministerium für Gesundheit
Weitere Informationen
Publikationsverlauf
Received
21. März 2005
Accepted after resubmission
19. September 2005
Publikationsdatum:
11. Dezember 2017 (online)
-
References
- 1 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. (editors) Haemostasis and Thrombosis, 3rd edn. Philadelphia: J.B. Lippincott; 1994: 169-83.
- 2 Scharrer I. The need for highly purified products to treat haemophilia B. Acta Haematol 1995; 94 (suppl) 2-7.
- 3 Makris M, Greaves M, Phillips WS. et al Emergency oral anticoagulant reversal: the relative efficiency of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
- 4 Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-7.
- 5 Kasper CK. Clinical use of factor IX concentrates: report on thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 642.
- 6 Ohga S, Saito M, Matsukazi A. et al Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy. Br J Haematol 1993; 84: 343-5.
- 7 Köhler M, Hellstern P, Lechler E. et al Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80: 399-402.
- 8 Mannucci PM, Bauer KA, Gringeri A. et al No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-11.
- 9 Philippou H, Adami A, Lane DA. et al High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76: 23-8.
- 10 Gray E, Tubbs J, Oates TA. et al Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-9.
- 11 Lowe GDO. Factor IX and thrombosis. Br J Haematol 2001; 115: 507-13.
- 12 Kusch M, Seitz R, König H. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes. Thromb Haemost 1998; 79: 778-83.
- 13 Hanker-Dusel C, Grundmann C, Eich S. et al Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 405-11.
- 14 Kingdon HS, Lundblad RL, Veltkamp JJ. et al Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-31.
- 15 Andrew M, Schmidt B, Mitchell L. et al Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30.
- 16 Wessler S, Reimer SM, Sheps MD. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
- 17 Thomas DP. Venous thrombosis and the “Wessler test”. Thromb Haemost 1996; 76: 1-4.
- 18 Lenting PJ, ter Maat H, Clijsters PPFM. et al Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem 1995; 270: 14884-90.
- 19 Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
- 20 Butenas S, van’t Veer C, Mann KG. Normal thrombin generation. Blood 1999; 94: 2169-78.